US 12,297,260 B2
DKK1 antibodies and methods of use
William Gleason Richards, Thousand Oaks, CA (US); Hsieng Sen Lu, Thousand Oaks, CA (US); Hua Zhu Ke, Newbury Park, CA (US); Chaoyang Li, Newbury Park, CA (US); and Frederick W. Jacobsen, Newbury Park, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Sep. 9, 2020, as Appl. No. 17/015,212.
Application 17/015,212 is a division of application No. 15/841,065, filed on Dec. 13, 2017, granted, now 10,800,839.
Application 15/841,065 is a continuation of application No. 13/878,619, granted, now 9,879,072, issued on Jan. 30, 2018, previously published as PCT/US2011/058025, filed on Oct. 27, 2011.
Claims priority of provisional application 61/407,128, filed on Oct. 27, 2010.
Prior Publication US 2021/0040189 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 39/395 (2006.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 39/3955 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 12 Claims
 
1. A method of treating a bone disorder comprising administering to a subject in need thereof a DKK1 antibody or fragment thereof, wherein the DKK1 antibody binds to human DKK1 and comprises six CDRs, wherein light chain CDR1, light chain CDR2, light chain CDR3, heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 of the six CDRs, respectively, comprise the amino acid sequences of: SEQ ID NOs: 115 to 120, SEQ ID NOs: 139 to 144, SEQ ID NOs: 187 to 192, SEQ ID NOs: 193-198, SEQ ID NOs: 205-210, SEQ ID NOs: 211-216, SEQ ID NOs: 217 to 222, or SEQ ID NOS: 223 to 228, respectively.